Skip to main content
Top
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Sarcoma | Research

Adult genitourinary sarcoma: analysis using hospital-based cancer registry data in Japan

Authors: Satoshi Nitta, Shuya Kandori, Kosuke Kojo, Shuhei Suzuki, Kazuki Hamada, Ichiro Chihara, Masanobu Shiga, Shotaro Sakka, Yoshiyuki Nagumo, Tomokazu Kimura, Bryan J. Mathis, Hiromitsu Negoro, Ayako Okuyama, Takahiro Higashi, Hiroyuki Nishiyama

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Background

Genitourinary sarcomas are rare in adults and few large-scale studies on adult genitourinary sarcoma are reported. We aimed to elucidate the clinical characteristics, survival outcomes, and prognostic factors for overall survival of adult genitourinary sarcoma in Japan.

Methods

A hospital-based cancer registry data in Japan was used to identify and enroll patients diagnosed with genitourinary sarcoma in 2013. The datasets were registered from 121 institutions.

Results

A total of 116 men and 39 women were included, with a median age of 66 years. The most common primary site was the kidney in 47 patients, followed by the paratestis in 36 patients. The most common histological type was liposarcoma in 54 patients, followed by leiomyosarcoma in 25 patients. The 5-year overall survival rates were 57.6%. On univariate analysis, male gender, paratestis as primary organ, and histological subtype of liposarcoma were predictive of favorable survival while primary kidney, bladder, or prostate gland location were predictive of unfavorable survival. On multivariate analysis, primary paratestis was an independent predictor of favorable survival while primary kidney, bladder, or prostate gland were independent predictors of unfavorable survival.

Conclusions

This is the first report showing the clinical characteristics and survival outcomes of adult genitourinary sarcoma in Japan using a real-world large cohort database.
Appendix
Available only for authorised users
Literature
Metadata
Title
Adult genitourinary sarcoma: analysis using hospital-based cancer registry data in Japan
Authors
Satoshi Nitta
Shuya Kandori
Kosuke Kojo
Shuhei Suzuki
Kazuki Hamada
Ichiro Chihara
Masanobu Shiga
Shotaro Sakka
Yoshiyuki Nagumo
Tomokazu Kimura
Bryan J. Mathis
Hiromitsu Negoro
Ayako Okuyama
Takahiro Higashi
Hiroyuki Nishiyama
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-11952-0

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine